Invega Sustenna/Xeplion/Invega Trinza/Trevicta (paliperidone) Disease area(s): Psychiatry Manufacturer(s): Johnson & Johnson 2024 Sales (USD): $4.22 billion Why it sold so well: In 2024, J&Js long-acting antipsychotic portfolio including Invega Sustenna, Xeplion, Invega Trinza and Trevicta registered global sales of $4.22 billion, reflecting a 2.6% year-over-year increase
The gummies are gluten-free, free of added sugar and third-party tested for purity and potency
Aquac Nutr 26:828841 Dias J, Arzel J, Corraze G, Kaushik SJ (2001) Effects of dietary l-carnitine supplementation on growth and lipid metabolism in European seabass ( Dicentrarchus labrax )
The metabolic benefits last about one week after each dose
the other with 20 percent for $24
Ans : Excess use may lead to mild side effects